N/A
Manufactured by APOTEX CORP.
14,068 FDA adverse event reports analyzed
Last updated: 2026-04-14
DAPTOMYCIN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by APOTEX CORP.. The most commonly reported adverse reactions for DAPTOMYCIN include DRUG INEFFECTIVE, OFF LABEL USE, ACUTE KIDNEY INJURY, PYREXIA, EOSINOPHILIC PNEUMONIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DAPTOMYCIN.
Out of 8,425 classified reports for DAPTOMYCIN:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 14,068 FDA FAERS reports that mention DAPTOMYCIN. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, ACUTE KIDNEY INJURY, PYREXIA, EOSINOPHILIC PNEUMONIA, RHABDOMYOLYSIS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list APOTEX CORP. in connection with DAPTOMYCIN. Always verify the specific product and NDC with your pharmacist.